Drug intelligence / Profile preview

NKTR-063

Development stage: Discontinued
Lead developer: Nektar Therapeutics
Modality: Small Molecules
Administration: Inhalation

Overview

NKTR-063 is an inhaled formulation of the glycopeptide antibiotic vancomycin, developed by Nektar Therapeutics using its proprietary pulmonary drug delivery technology. The drug was designed to treat Gram-positive pulmonary infections, including pneumonia caused by methicillin-resistant *Staphylococcus aureus* (MRSA). By delivering the antibiotic directly to the site of infection via inhalation, NKTR-063 aimed to achieve high therapeutic concentrations in the lungs while reducing the systemic side effects typically associated with intravenous vancomycin administration. The program was evaluated in preclinical studies but did not progress to late-stage clinical development.

Other names: inhaled vancomycin

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)

Beyond the preview

Go deeper on NKTR-063.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKTR-063.

Explore the full profile